Glaucoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Glaucoma – Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Glaucoma
- The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects
- The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Glaucoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Glaucoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4B Technologies (Suzhou) Co LtdAbbVie Inc
AC Immune SA
Adtech Pharma Inc
Advanced Vision Technologies (New York)
AffaMed Therapeutics US Inc
Agency for Science, Technology and Research
Annexon Inc
Arctic Vision Shanghai Biotechnology Co Ltd
Asha Therapeutics LLC
Astellas Pharma Inc
Austin Biosciences Corp
Avirmax Inc
AXONIS Therapeutics Inc
Berlin Cures Holding AG
Betaliq Inc
Biorchestra Co Ltd
Biozeus Pharmaceutical SA
BrainEver SAS
Broadwing Bio
BSIM Therapeutics SA
CalciMedica Inc
Calpain Therapeutics Pty Ltd
Cancer Research UK
CdmoGen Co Ltd
Celiaz Co Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Character Biosciences Inc
Chong Kun Dang Pharmaceutical Corp.
Cloudbreak Therapeutics LLC
Connexin Therapeutics Inc
D-Sight SL
D. Western Therapeutics Institute Inc
Diorasis Therapeutics
Dompe Farmaceutici SpA
Eli Lilly and Co
Emmecell LLC
Evotec SE
Eye Bio Korea Co Ltd
Eyevensys SAS
FasT Biopharma Ltd
Future Medicine Co Ltd
Galimedix Therapeutics Ltd
Glaukos Corp
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Runer Ophthalmic Biotechnology Co Ltd
Gurus BioPharm Inc
Handok Inc
Hefei Starry Gene Biotechnology Co Ltd
HitGen Inc
HK inno.N Corp
Human Cell Corp
Huons Global Co Ltd
Icahn School of Medicine at Mount Sinai
ID Pharma Co Ltd
Ildong Pharmaceutical Co Ltd
Incannex Healthcare Ltd
Indiana University-Purdue University Indianapolis
Industrial Technology Research Institute
Ingenia Therapeutics Inc
InMed Pharmaceuticals Inc
Isarna Therapeutics GmbH
IVIEW Therapeutics Inc
jCyte Inc
Jenivision Inc
Kodiak Sciences Inc
Korea Research Institute of Chemical Technology
Kowa Co Ltd
KP Biosciences Inc
Kukje Pharmaceutical Industry Co Ltd
KYORIN Pharmaceutical Co Ltd
Kyoto University
Laboratoires Thea SA
Laboratorios Salvat SA
Laboratorios Sophia SA de CV
LayerBio Inc
Lee's Pharmaceutical Holdings Ltd
Life Biosciences Inc.
Macquarie University
Matrix Biomed Inc
Medical University of South Carolina
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
MimeTech Srl
Mitotech SA
MT-act
MyX Therapeutics Inc
NeurAegis Inc
Neuraly Inc
Neurizon Pharma GBR
Neurophoenix
Neuroptika Inc
NeuroScientific Biopharmaceuticals Ltd
Neurotech Pharmaceuticals Inc
Nexel Co Ltd
NicOx SA
NoNO Inc
Northwestern University
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
Novoron Bioscience Inc
Ocular Therapeutix Inc
Oculis Holding AG
Oculo Therapy LLC
Oculogenex Inc
Ocumension Therapeutics Co Ltd
Ocuphire Pharma Inc
Oncolys BioPharma Inc
ONL Therapeutics Inc
Optus Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd
Palatin Technologies Inc
Pasteur Institute
Perceive Biotherapeutics Inc
Perfuse Therapeutics Inc
pH Pharma Co Ltd
Pharmadrug Inc
Pharminogen Inc
Pinotbio Inc
PolyActiva Pty Ltd
Profarma
Q BioMed Inc
Qlaris Bio Inc
Quark Pharmaceuticals Inc
Qurgen Inc
Radikal Therapeutics Inc
Rebio Technologies Ltd
Rebus Holdings Inc
Regeneron Pharmaceuticals Inc
ReNetX Bio
Retinset SL
Ripple therapeutics Corp
Roca Therapeutics SAS
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
SIFI SpA
Skye Bioscience Inc
Sun Pharmaceutical Industries Ltd
Sustained Nano Systems LLC
Suzhou Ribo Life Sciences Co Ltd
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TALLC Inc
Tarsier Pharma Ltd
TearClear Corp
Teraclon IDF SL
Theratocular Biotek Co Ltd
TikoMed AB
Tisbury Pharmaceuticals Ltd
Toa Eiyo Ltd
Topadur Pharma AG
Turn Biotechnologies Inc
University Medical Center Mainz
University of Arizona
University of Birmingham Medical School
University of Bristol
University of California San Diego
University of Minnesota
University of North Carolina at Chapel Hill
University of Pennsylvania
University of Wisconsin Madison
ViSci Ltd
Visiox Pharma LLC
Visus Therapeutics Inc
Viva Vision Biotech
Whitecap Biosciences LLC
Wuhan Neurophth Biological Technology Ltd
Xilingyuan Pharmaceutical Co Ltd